The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.075
Bid: 2.95
Ask: 3.20
Change: 0.20 (6.96%)
Spread: 0.25 (8.475%)
Open: 2.875
High: 3.075
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BLOCK LISTING SIX MONTHLY RETURN

16 Jul 2018 08:53

RNS Number : 7205U
Allergy Therapeutics PLC
16 July 2018
 

BLOCK LISTING SIX MONTHLY RETURN

 

Information provided on this form must be typed or printed electronically and provided to an ris.

 

(Note: Italicised terms have the same meaning as given in the Listing Rules.)

Date: 11 JULY 2018

 

Name of applicant:

ALLERGY THERAPEUTICS PLC

Name of scheme:

Allergy Therapeutics plc 2013 Long Term Incentive Plan

Period of return:

From:

21 Nov 2017

To:

11 July 2018

Balance of unallotted securities under scheme(s) from previous return:

10,000,000

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

-

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

 2,050,848

 

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

 7,949,152

 

 

Name of contact:

Sara Goldsbrough

Telephone number of contact:

+44 (0) 7966 165719 

 

 

Total Voting Rights

 

The total number of voting rights of the company is 596,168,616. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the share capital of the company under the FCA's Disclosure and Transparency Rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRSFSSWMFASEIW
Date   Source Headline
14th May 20197:00 amRNSHoldings in Company
13th May 20196:14 pmRNSHolding(s) in Company
13th May 20194:41 pmRNSSecond Price Monitoring Extn
13th May 20194:35 pmRNSPrice Monitoring Extension
7th May 20197:00 amRNSResearch Published on Adjuvant Systems
25th Apr 20197:00 amRNSRegulatory and Trading Update
18th Mar 20194:41 pmRNSSecond Price Monitoring Extn
18th Mar 20194:36 pmRNSPrice Monitoring Extension
18th Mar 201911:30 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Take an objective view
18th Mar 201911:05 amRNSSecond Price Monitoring Extn
18th Mar 201911:00 amRNSPrice Monitoring Extension
18th Mar 20199:05 amRNSSecond Price Monitoring Extn
18th Mar 20199:00 amRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSTop Line Phase III results from B301 trial
6th Mar 201912:10 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Strong operating performance driving market share
6th Mar 20197:00 amRNSInterim Results
17th Jan 20199:56 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share
16th Jan 20197:00 amRNSTrading Update & Notice of Results
29th Nov 20185:59 pmRNSHoldings in Company
27th Nov 20181:12 pmRNSResult of AGM
27th Nov 20187:00 amRNSAGM Trading Update
12th Nov 201812:00 pmRNSPresentation at Jefferies Healthcare Conference
8th Nov 20187:00 amRNSDirectorate Change
7th Nov 20186:06 pmRNSHoldings in Company
2nd Nov 20187:00 amRNSGrant of Awards under Long Term Incentive Plan
24th Oct 20181:25 pmRNSHoldings in Company
24th Oct 20187:00 amRNSDirector/PDMR Shareholding
23rd Oct 20185:29 pmRNSAnnual Report and Accounts
23rd Oct 20183:28 pmRNSHoldings in Company
27th Sep 20187:15 amEQSHardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth
26th Sep 20187:00 amRNSPreliminary Results
8th Aug 20187:00 amRNSNotice of Results
27th Jul 20185:26 pmRNSHolding(s) in Company
26th Jul 201812:02 pmRNSHolding(s) in Company
19th Jul 201810:19 amRNSResults of Placing and Subscription
19th Jul 20187:00 amRNSProposed placing & subscription to raise £10.6m
16th Jul 20188:53 amRNSBLOCK LISTING SIX MONTHLY RETURN
13th Jul 20189:40 amEQSHardman & Co Research: Allergy Therapeutics (AGY): Steady performance in a tough market
12th Jul 20187:00 amRNSTrading Update
25th Jun 20187:52 amRNSPositive data of Pollinex Quattro Grass vaccine
29th May 20187:00 amRNSPositive data with house-dust mite immunotherapy
21st May 201812:25 pmEQSHardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration
21st May 20187:00 amRNSPositive top-line results from Grass Ph II study
14th May 20187:00 amRNSPublication of MCT Adjuvant Data
16th Mar 20183:38 pmRNSGrant of Awards under Long Term Incentive Plan
16th Mar 201812:53 pmRNSDirector/PDMR Shareholding
7th Mar 20189:30 amRNSHardman: Clinical development towards submission
7th Mar 20187:00 amRNSInterim Results
28th Feb 20187:00 amRNSPolyvac® Peanut CMO appointed
12th Feb 20187:00 amRNSCompletion of recruitment in PQ Grass Ph II trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.